On the other hand, a knockdown of miR-122 alleviated lipid deposition through the upregulation of SIRT1, indicating that miR-122 acts through regulating SIRT1 and may be a useful diagnostic biomarker and therapeutic target in NAFLD [263]. Here, SIRT1 is linked to metabolic dysfunction-associated steatotic liver disease.